ReviewFrontiers in pharmacology2026
Recent developments in quercetin nanomedicine and applications in osteoarthritis and rheumatoid arthritis therapies.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quercetin has attracted increasing attention in the research of treatments for rheumatoid arthritis and osteoarthritis due to its excellent anti-inflammatory, antioxidant, and joint-protective effects. However, the bioavailability of quercetin is relatively low, primarily due to its poor solubility, rapid metabolism, and high clearance rate. Nanotechnology offers new opportunities to enhance the bioavailability of quercetin. Nanoformulations possess many advantages, such as a larger surface area, which can effectively improve the solubility of quercetin. Encapsulating quercetin in nanocarriers can prolong its residence time in the body, thereby improving its bioavailability and therapeutic efficacy. Targeted delivery can be achieved by modifying the surface of nanocarriers with ligands, allowing for direct transport of the drug to the site of injury and increasing the concentration at the lesion site. Nanocarriers can improve drug targeting and release behavior by adjusting their surface properties, thereby enhancing therapeutic effects. This article first summarizes the general preparation methods, drug-loading approaches, and common nanoformulations for quercetin. It then lists and summarizes the applications of quercetin nanoparticle formulations in rheumatoid arthritis and osteoarthritis. Finally, it concludes with a summary and outlook on the clinical applications and challenges associated with quercetin nanoformulations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.